Venetoclax: all 546 studies that test it

Page 3 of 6. Open to participants first (240), then studies with results posted, then the rest; newest registration first within each.

• Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)RecruitingNCT05183035Phase 3
• Zanubrutinib and Venetoclax in CLL (ZANU-VEN)RecruitingNCT05168930Phase 2
• Efficacy of Venetoclax in Combination With Rituximab in Waldenström's MacroglobulinemiaRecruitingNCT05099471Phase 2
• A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic LeukemiaRecruitingNCT05091424Phase 1
• Study of Venetoclax and Azacitidine in Advanced BCR-ABL Negative Myeloproliferative NeoplasmsRecruitingNCT05074355Phase 2
• A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALLNot yet recruitingNCT05054465Phase 1/2
• Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in RemissionRecruitingNCT05010772Phase 1
• ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeRecruitingNCT05010122Phase 1/2
• Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell TransplantationRecruitingNCT05005299Phase 1
• Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 TrialRecruitingNCT04941716Phase 2
• Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent FailureRecruitingNCT04905810Phase 2
• Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)RecruitingNCT04895436Phase 2
• Avo In R/R And Previously Untreated MCLRecruitingNCT04855695Phase 1/2
• Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic LymphomaRecruitingNCT04840602Phase 2
• Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid NeoplasmsRecruitingNCT04797767Phase 1/2
• Lymph Node Microenvironment Modifications in Patients With CLL Treated With Venetoclax-based RegimensNot yet recruitingNCT04790045Phase 4
• Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL)RecruitingNCT04758975Phase 2
• Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDSRecruitingNCT04708054Phase 2/3
• Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2RecruitingNCT04628026Phase 3
• Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AMLRecruitingNCT04588922Phase 1/2
• Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL StudyRecruitingNCT04269902Phase 3
• A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)RecruitingNCT04256317Phase 2/3
• Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell NeoplasmRecruitingNCT04216524Phase 2
• Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaRecruitingNCT04169737Phase 2
• Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative NeoplasmRecruitingNCT04140487Phase 1/2
• Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection or Early TreatmentRecruitingNCT03868722Phase 2/3
• Venetoclax and Lintuzumab-Ac225 in AML PatientsRecruitingNCT03867682Phase 1/2
• Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute LeukemiaRecruitingNCT03826992Phase 1
• Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic SyndromeRecruitingNCT03661307Phase 1/2
• Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid LeukemiaRecruitingNCT03629171Phase 2
• Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid LeukemiaRecruitingNCT03586609Phase 2
• A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological MalignanciesRecruitingNCT03557619Phase 1
• Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell LymphomaRecruitingNCT03523975Phase 1/2
• Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic MalignanciesRecruitingNCT03471260Phase 1/2
• Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell LymphomaRecruitingNCT03223610Phase 1/2
• Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid LeukemiaRecruitingNCT03214562Phase 1/2
• SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)RecruitingNCT03113643Phase 1
• Study of Biomarker-Based Treatment of Acute Myeloid LeukemiaRecruitingNCT03013998Phase 2/3
• Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CRRecruitingNCT02416388Phase 2/3
• Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid LeukemiaRecruitingNCT02115295Phase 2
• Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell TransplantTerminatedNCT05799079Phase 2Results posted
• Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBLTerminatedNCT05464836Phase 2Results posted
• Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid MalignanciesCompletedNCT05371054Phase 1/2Results posted
• Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AMLTerminatedNCT05275439Phase 1Results posted
• Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous SystemActive, not recruitingNCT05211336Phase 1Results posted
• A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic SyndromesTerminatedNCT05168202Phase 1Results posted
• Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell LymphomaTerminatedNCT05025423Phase 2Results posted
• Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1TerminatedNCT04874194Phase 1/2Results posted
• Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia PatientsActive, not recruitingNCT04817241Phase 1/2Results posted
• A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS ParticipantsTerminatedNCT04812548Phase 2Results posted
• DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic LeukemiaTerminatedNCT04752163Phase 1/2Results posted
• A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular LymphomaTerminatedNCT04722601Phase 1/2Results posted
• Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell LymphomaTerminatedNCT04659044Phase 2Results posted
• Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell MalignanciesCompletedNCT04599634Phase 1Results posted
• Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic SyndromeCompletedNCT04487106Phase 2Results posted
• Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell LymphomaCompletedNCT04477486Phase 2Results posted
• Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid LeukemiaTerminatedNCT04435691Phase 1/2Results posted
• A Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast CancerTerminatedNCT04298918Phase 1/2Results posted
• A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 MutationCompletedNCT04285567Phase 3Results posted
• Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid LeukemiaCompletedNCT04277442Phase 1Results posted
• Ibrutinib + Venetoclax in Untreated WMActive, not recruitingNCT04273139Phase 2Results posted
• APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid MalignanciesCompletedNCT04214860Phase 1Results posted
• A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)TerminatedNCT04161885Phase 3Results posted
• A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for ChemotherapyTerminatedNCT04150029Phase 2Results posted
• Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative DiseaseCompletedNCT04146038Phase 2Results posted
• A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional ChemotherapyCompletedNCT04102020Phase 3Results posted
• Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113CompletedNCT04070768Phase 1Results posted
• A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid TumorsTerminatedNCT04029688Phase 1/2Results posted
• Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or VenetoclaxTerminatedNCT04016805Phase 2Results posted
• A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic LeukemiaCompletedNCT03873493Phase 2Results posted
• Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell LymphomaActive, not recruitingNCT03872180Phase 2Results posted
• Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of AgeCompletedNCT03834688Phase 2Results posted
• Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)TerminatedNCT03801525Phase 2/3Results posted
• Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic LeukemiaActive, not recruitingNCT03737981Phase 3Results posted
• Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid LeukemiaTerminatedNCT03735875Phase 1/2Results posted
• Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid LeukemiaTerminatedNCT03634228Phase 1/2Results posted
• Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic LeukemiaCompletedNCT03609593Phase 2Results posted
• A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor TherapyTerminatedNCT03584009Phase 2Results posted
• Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin LymphomaCompletedNCT03583424Phase 1/2Results posted
• Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLLActive, not recruitingNCT03580928Phase 2Results posted
• Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous LeukemiaTerminatedNCT03576547Phase 1/2Results posted
• Venetoclax and Azacitidine for Non-Elderly Adult Patients With Acute Myeloid LeukemiaCompletedNCT03573024Phase 2Results posted
• A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple MyelomaTerminatedNCT03567616Phase 2Results posted
• Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RSActive, not recruitingNCT03534323Phase 1/2Results posted
• Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell LymphomaCompletedNCT03534180Phase 2Results posted
• A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)Active, not recruitingNCT03462719Phase 3Results posted
• OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT03390296Phase 1/2Results posted
• A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple MyelomaCompletedNCT03312530Phase 1/2Results posted
• Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid LeukemiaCompletedNCT03226418Phase 2Results posted
• A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaTerminatedNCT03136497Phase 1Results posted
• Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line TherapyCompletedNCT03113422Phase 2Results posted
• Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)CompletedNCT03112174Phase 3Results posted
• A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive ChemotherapyCompletedNCT03069352Phase 3Results posted
• Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLLCompletedNCT03045328Phase 2Results posted
• A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction TherapyActive, not recruitingNCT02993523Phase 3Results posted
• A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent).CompletedNCT02980731Phase 3Results posted
• Ibrutinib and Venetoclax in Relapsed and Refractory Follicular LymphomaCompletedNCT02956382Phase 1/2Results posted
• Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)CompletedNCT02910583Phase 2Results posted
• A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL)CompletedNCT02756611Phase 3Results posted
• A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard TherapyCompletedNCT02755597Phase 3Results posted

← Venetoclax overview